Defective Sequencing Reagents to Cost Illumina up to $23M in 2009; Company Says Problem is Solved
November 03, 2009
Defective Sequencing Reagents to Cost Illumina up to $23M in 2009; Company Says Problem is Solved
The faulty reagent kits, a problem that Illumina said it first discovered in September and has since rectified, cost the company up to $8 million in lost revenue in the third quarter. The issue is expected to decrease revenues in the fourth quarter by up to $15 million.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Books Orders for More than 135 MiSeqs, Starts Early-Access Shipments
August 2, 2011 / In Sequence - Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue
February 9, 2010 / In Sequence - Illumina Obtains More Than 55 Gb from GA; Expects Large NIH Stimulus Awards for Sequencing
July 28, 2009 / In Sequence - Illumina Lowers Q2 Revenue Expectations Despite Growth in Sequencing Business
July 7, 2009 / In Sequence - Amid Declining Revenues, Illumina Plans to Restructure, Focus on Clinical Market
October 25, 2011 / In Sequence